Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-018-23195-8 http://scihub22266oqcxt.onion/10.1038/s41598-018-23195-8 C5869697!5869697!29588458     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2018 ; 8 (ä): ä Nephropedia Template TP {{tp|p=29588458|t=2018. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression |pdf=|usr=}}{{29588458}} gab.com Text Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=29588458 #FOAvip Reversal of cancer gene expression is predictive of therapeutic potential and can be used to find new indications for existing drugs (drug repositioning). Gene expression reversal potential is currently calculated, in almost all studies, by pre-aggregating all tumour samples into a single group signature or a limited number of molecular subtype signatures. Here, we investigate whether drug repositioning based on individual tumour sample gene expression signatures outperforms the use of tumour group and subtype signatures. The tumour signatures were created using 534 tumour samples and 72 matched normal samples from 530 clear cell renal cell carcinoma (ccRCC) patients. More than 20,000 drug signatures were extracted from the CMAP and LINCS databases. We show that negative enrichment of individual tumour samples correlated (Spearman?s rho?=?0.15) much better with the amount of differentially expressed genes in drug signatures than with the tumour group signature (Rho?=?0.08) and the 4 tumour subtype signatures (Rho 0.036-0.11). Targeted drugs used against ccRCC, such as sirolimus and temsirolimus, which could not be identified with the pre-aggregated tumour signatures could be recovered using individual sample analysis. Thus, drug repositioning can be personalized by taking into account the gene expression profile of the individual?s tumour sample. Twit Text FOAVip Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=29588458 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29588458 #FOAvip English Wikipedia <ref>{{Cite pmid|29588458}}</ref> Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression #MMPMID29588458 Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ Sci Rep 2018[]; 8 (ä): ä PMID29588458show ga Reversal of cancer gene expression is predictive of therapeutic potential and can be used to find new indications for existing drugs (drug repositioning). Gene expression reversal potential is currently calculated, in almost all studies, by pre-aggregating all tumour samples into a single group signature or a limited number of molecular subtype signatures. Here, we investigate whether drug repositioning based on individual tumour sample gene expression signatures outperforms the use of tumour group and subtype signatures. The tumour signatures were created using 534 tumour samples and 72 matched normal samples from 530 clear cell renal cell carcinoma (ccRCC) patients. More than 20,000 drug signatures were extracted from the CMAP and LINCS databases. We show that negative enrichment of individual tumour samples correlated (Spearman?s rho?=?0.15) much better with the amount of differentially expressed genes in drug signatures than with the tumour group signature (Rho?=?0.08) and the 4 tumour subtype signatures (Rho 0.036-0.11). Targeted drugs used against ccRCC, such as sirolimus and temsirolimus, which could not be identified with the pre-aggregated tumour signatures could be recovered using individual sample analysis. Thus, drug repositioning can be personalized by taking into account the gene expression profile of the individual?s tumour sample. äPersonalised drug repositioning for Clear Cell Renal Cell Carcinoma us(epmc).pdf DeepDyve Pubget Overpricing